The medicines are from reputed pharmaceutical manufacturers and come with a long-dated shelf life of up to 2023
Transasia Bio-Medicals has donated over five lakh tablets worth more than Rs 50 lakhs for the recovery of COVID-19 patients. These medicines have been identified as a part of India’s COVID-19 treatment protocol and are enabling in mitigating the widespread human impact of the pandemic. The medicines are from reputed pharmaceutical manufacturers and come with a long-dated shelf life of up to 2023.
The procurement and distribution of the medicines have been executed by the Vazirani Foundation, the CSR arm of Transasia Bio-Medicals and closely coordinated by Transasia’s team of over 700 on-field personnel who have a deep presence across the country, along with various charitable trusts.
Speaking on the initiative, Mala Vazirani, Executive Director, Transasia Bio-Medicals said, “Today, we are all experiencing a truly unprecedented situation. Over the past few months, India has been reeling under increased cases of COVID-19 that has strained the country’s health resources to the limit.”
She further added, “We are honoured to support those fighting tirelessly to treat our many fellow Indians suffering from COVID-19. Transasia has stepped up its ongoing efforts to fight the virus. In our endeavour to make quality healthcare available to the needy and underprivileged, we are partnering with NGOs and mission hospitals to fight against this disease and are quickly working to mobilise the largest humanitarian relief effort in our company’s history.”
This initiative comes close on the heels of the organisation’s recent COVID-relief efforts, whereby the company donated equipment worth more than Rs 3.30 crores, which included 200 BiPAP machines, 43 cell counters and 32 coagulation analysers, that are critical for COVID patients and aid in monitoring the disease severity.
